Pharmacokinetic Characterization of Nano-emulsion Vitamin A, D and E (LaVita) in Rats

Young-Ju Lee,1 Min Kwon,1 Tae-Hwan Kim,2 Kyun Kim,1 Sang-Hee Jeong1 and Hee-Ra Chang1*

1Hoseo Toxicological Research Center, Hoseo University, Asan, 336-795, Korea
2Technology Institute, KNBP Inc., Yesan, 340-861, Korea

Received: 1 June 2011 / Accepted: 24 June 2011
ⓒ The Korean Society of Environmental Agriculture

Abstract

BACKGROUND: Bioavailability enhancement by solubilization of lipophilic drugs in nano-emulsion has been reported and it may be useful in pharmaceutical and nutraceutical products. This study was performed to compare in vivo bioavailability of nano-emulsion formulation with that of the general product as control.

METHODS AND RESULTS: The pharmacokinetics assessment of Vitamin A, D and E complex of nano-emulsion formulation (LaVita), in comparison to the general product, was performed in the male rat plasma by a single oral dose at 20 mL/kg body weight (n=3/group). For nano-emulsion formulation (LaVita), Cmax of vitamin A and E in plasma were much higher and the area under the curve (AUC) of vitamin A, D and E were 14-63% higher, and the half-life of vitamin E was 2-fold longer than the general product. According to statistical analysis, each Cmax of vitamin A, D & E was significantly higher (p<0.01, 0.05 and 0.01, respectively) than that of general product. Half-life of vitamin A was significantly higher (p<0.01) and AUC of vitamin A and D were also significantly higher than the general product.

CONCLUSION(s): Considering significant increment of Cmax and AUC, LaVita made of nano-emulsion could be more effective the absorption rate and extent for bioavailability of vitamin A, D & E than those of general product.

Key Words: Bioavailability, Fat-soluble vitamin, Nano-emulsion, Pharmacokinetics, Plasma

Introduction

LaVita, nano-emulsion vitamin A, D and E, was a newly developed by Korea BNP, INC., for usage in drinking water or feeds of poultry and livestock. Vitamin A, D and E, have important functions of the human and animal body such as vision (Vitamin A), calcium absorption (Vitamin D) and antioxidant (Vitamin E) (Heudi et al., 2004; Mendoza et al., 2003). These functions are affected by the fat-soluble vitamin concentration and many pathological signs appear with deficiency or overdose of vitamins (Gomis et al., 1994). Our body has a disposing capability of excess vitamins resulting in a loss to the system of the vitamins taken. Therefore, a critical aspect of vitamin A, D and E supplements is the ability to absorb the composition into the body and maintain effectiveness.

Many unique aspects of nano-emulsions with droplet sizes in the range of 20-200 nm attributes to be utilized within an increasing number of industrial products, including food, pharmaceuticals, cosmetics, personal care products, and chemicals (Lee et al., 2011; Solans et al., 2005). Nano-emulsions were proposed for application in pharmacy as delivery systems of poorly permeable and highly lipophilic drugs for enhancing solubility and permeation properties (Brusewitz et al., 2007; Gutierrez et al., 2008; Hatanaka et al.,...
2010; Solans et al., 2005; Tadros et al., 2004). Enhancement of bioavailability by solubilization of lipophilic drugs in nano-emulsion has been reported and then in vivo and in vitro studies confirmed that nano-emulsion enhanced the penetration of vitamin E acetate (Kang et al., 2002).

The purpose of this present study was to evaluate the pharmacokinetic profiles (Tmax, Cmax, half-life and AUC) of nano-emulsion vitamin A, D and E in rats by an oral application, in comparison to general product.

Materials and Methods

Chemicals

LaVita and general product were provided by Korea BNP, INC. The contents of vitamin A, D and E in these products were 50,000,000 IU/L, 5,000,000 IU/L and 20,000 IU/L, respectively. Vitamin A (Retinol palmitate, 94.7%), vitamin D (cholecalciferol, 98%), Vitamin E-OAc (DL-α-tocopherol acetate, 97.8%) and Vitamin E-OH (DL-all-rac-α-tocopherol, 95.5%) were purchased from Sigma-Aldrich Co. (St. Louis, MO). High-performance liquid chromatography (HPLC) grade methanol, acetonitrile, hexane and water were purchased from Merck, Germany. All of other reagents were of analytical grade (Junsei Chemical Co., Japan).

Animals and dose administration

Male Sprague-Dawley 9 rats, approximately 5 weeks old, were obtained from Orient Bio Inc. (Korea) and acclimated for 3 weeks before dosing. The animals were housed in polycarbonated cages at 22 ± 3°C and 50 ± 20% humidity with a 12 h light/dark cycle. The food (LabDiet®, Orient Bio Inc.) and water were available adlibitum during the study. For the study, rats weighing 372.6±14.6 g were separated to three dose groups consist of 3 rats per group (blank, treatment of general product and treatment of LaVita) and were orally administrated at a single dose of 20 mL containing 1,000,000 IU of vitamin A, 100,000 IU of vitamin D and 400 IU of vitamin E per kg body weight (n=3/group).

Sample collection

Blood samples (2 mL) were taken from the retro-orbital of each rat at 0.5, 3, 6, 24, 48, 72, 168, 196 h after oral administration. Blood samples were collected in heparinized tubes and centrifuged at 15000 rpm for 10 min at room temperature to separate plasma.

Sample preparation

Three replicate aliquots (0.4 mL) of plasma in 2 mL tube were added to 0.3 ml of 20% isopropanol in methanol and mixed by vortexing for 15 sec. The mixture was extracted with 0.7 mL of hexane, mixed for 3 min, centrifuged at 10,000 rpm for 3 min, and the hexane layer was removed. The aqueous phase was further extracted twice in the same way. The total extracts were evaporated to dryness under a nitrogen stream, and the residue was re-dissolved in 0.2 ml of 50% methanol in chloroform for HPLC analysis.

HPLC analysis

Determination of vitamin A, D, E-OAc (acetate) and E-OH (phenol) concentration were performed on the Agilent 1200 Series HPLC system equipped with Diode-Array Detector (DAD). A reverse-phase Hypersil™ Gold column (250 mm 4.6 mm, 5-μm particle; Thermo Scientific) was used at 40 C and the flow rate was 1.0 mL/min. Detection monitoring was performed at 330 nm for vitamin A and 280 nm for vitamin D and E E (-OAc and -OH). The elution system for three vitamins was described Table 1. Under these conditions, the elution times of vitamin A, D, and E were 4, 6, and 18 min, respectively.

Table 1. The elution methods for vitamin A, D and E analyses by HPLC

<table>
<thead>
<tr>
<th>Vitamin</th>
<th>Elution System</th>
<th>Mobile Phase</th>
<th>time</th>
<th>% (A)</th>
<th>% (B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Isocratic</td>
<td>Acetonitrile</td>
<td>Methanol</td>
<td>NA</td>
<td>0-21</td>
</tr>
<tr>
<td>D &amp; E</td>
<td>Gradient</td>
<td>Acetonitrile</td>
<td>Methanol</td>
<td>Water</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25</td>
<td>10</td>
</tr>
</tbody>
</table>

NA: Not applicable
Table 2. Recovery, limit of detection and limit of quantification for determination of vitamin A, D and E in rat plasma

<table>
<thead>
<tr>
<th>Vitamin</th>
<th>Fortified level (mM)</th>
<th>Recovery ± CV$^{13}$ (%)</th>
<th>LOD$^{20}$ (mM)</th>
<th>LOQ$^{30}$ (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0.005</td>
<td>91.9 ± 6.3</td>
<td>0.0005</td>
<td>0.0015</td>
</tr>
<tr>
<td></td>
<td>0.0125</td>
<td>87.9 ± 5.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>0.005</td>
<td>82.4 ± 8.4</td>
<td>0.00025</td>
<td>0.00075</td>
</tr>
<tr>
<td></td>
<td>0.0125</td>
<td>81.6 ± 2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>-OAc</td>
<td>0.005</td>
<td>90.4 ± 6.5</td>
<td>0.0005</td>
</tr>
<tr>
<td></td>
<td>0.0125</td>
<td>80.5 ± 7.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-OH</td>
<td>0.005</td>
<td>89.5 ± 2.3</td>
<td>0.0005</td>
</tr>
<tr>
<td></td>
<td>0.0125</td>
<td>83.4 ± 2.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^{13}$ Coefficient of variation = standard deviation / average 100

$^{20}$ LOD: Limit of Detection

$^{30}$ LOQ: Limit of Quantification (3 times of LOD)
reproducibility of 91.9±6.3, 82.4±8.4, 90.4±6.5 and 89.5±2.3% at 0.005 mM and 87.9±5.0, 81.6±2.6, 80.5±7.8 and 83.4±2.0% at 0.0125 mM, respectively, indicating that good extraction method is established.

Plasma Concentration and Pharmacokinetic Analysis

The plasma concentrations of vitamin A, D and E (-OAc and -OH) in rat were determined by HPLC analysis (Fig. 2, 3). Vitamin E-OAc is the most commonly used form in vitamin E supplements, but vitamin E-OAc is biologically inactive and rapidly hydrolyzed to the vitamin E-OH in the plasma (Burton et al., 1988, 1990; Gonzalez et al., 1990; Hidiroglou et al., 1994). Therefore, the level of vitamin E was calculated by summing the concentration of E-OH and E-OAc form. The mean plasma concentration versus time profiles in rat plasma after single dose administration is showed in Fig. 4. The plasma concentration of LaVita was higher than general product in rat except for 24 h of vitamin A.

![Fig. 2. Representative chromatograms of vitamin A in plasma sample after oral administration of LaVita and general product by HPLC analysis.](image)

![Fig. 3. Representative chromatograms of vitamin D and E (-OAc and -OH) in plasma sample after oral administration of LaVita and general product by HPLC analysis.](image)

![Fig. 4. Vitamin A, D and E concentrations in rat plasma after a single oral administration of LaVita and general product.](image)

The pharmacokinetic parameters of vitamin A, D, and E are showed in Table 3. The time required to reach peak plasma concentration (T\text{max}) of Vitamin A after dosing was 6 h in LaVita and general product. Mean peak plasma concentrations (C\text{max}) were 0.39±0.01 mM for LaVita and 0.25±0.03 mM for general product. The other pharmacokinetic parameters showed that the half-lives for LaVita and general product were 12.70 and 10.52 h, respectively and the area under the plasma concentration-time curve (AUC) for LaVita was higher than for the general product. According to statistical analysis, C\text{max} and half-life of vitamin A in LaVita were significantly higher (p<0.01) than general product.
Table 3. The pharmacokinetic parameters of vitamin A, D and E in LaVita and general product after single oral administration

<table>
<thead>
<tr>
<th>Parameters</th>
<th>VIT A</th>
<th>VIT D</th>
<th>VIT E (OAc+OH)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>General Product</td>
<td>LaVita</td>
<td>General Product</td>
</tr>
<tr>
<td>Tmax (h)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>6.00±0.0</td>
<td>6.00±0.0</td>
<td>24.00±0.0</td>
</tr>
<tr>
<td>Cmax (mM)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.25±0.03</td>
<td>0.39±0.01&lt;sup&gt;3&lt;/sup&gt;</td>
<td>0.008±0.001</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2,λ&lt;/sub&gt;(h)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>10.52±2.21</td>
<td>12.70±0.40&lt;sup&gt;3&lt;/sup&gt;</td>
<td>25.35±6.87</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;all&lt;/sub&gt; (μg・h/mL)&lt;sup&gt;4&lt;/sup&gt;</td>
<td>8.64±0.35</td>
<td>9.87±1.53</td>
<td>0.48±0.03</td>
</tr>
</tbody>
</table>

<sup>1</sup> time to maximum concentration  
<sup>2</sup> maximum concentration  
<sup>3</sup> half-life  
<sup>4</sup> area under the curve of plasma concentration versus time from t=0 to t=∞ after oral administration  
<sup>5</sup> p value < 0.01  
<sup>6</sup> p value < 0.05

The calculated Tmax values of vitamin D for LaVita and general product were 24 h after oral administration. The Cmax of LaVita (0.01±0.001 mM) was significantly higher (p<0.05) than that of general product (0.008±0.001 mM) and the AUC was 1.2-fold higher (p<0.01) than general product. The half-life of vitamin D in LaVita showed no significant difference compared with that of general product, but it was 1 h longer than general product.

The observed Tmax values of Vitamin E were 24 and 32 h in comparison of LaVita and general product, respectively. Both Cmax and the AUC of vitamin E in LaVita were significantly higher than general product (p<0.01). The half-life was 2.2-fold longer than general product, but it is not significantly different.

From these results, the bioavailability of vitamin A, D and E, LaVita, in rat exhibited a significant improvement in the pharmacokinetics parameters, Cmax, AUC and half-life, indicating that nano-emulsion formulation is increased oral absorption of vitamin A, D and E compared with general product.

LaVita’s particle size (≤100nm) was much smaller than general product (100-20,000 nm) so the larger surface area for the active ingredients may increase absorption extent and rate. Thus, it has been reported that the bioavailability of drug could be highly influenced by the formulation type (Taha et al., 2007). Nano-emulsions in pharmacy generally improves the solubility and permeability for highly lipophilic drugs for using in the nutrition field and then bioavailability enhancement has been reported (Brusewitz et al., 2007; Hatanaka et al., 2010; Kang et al., 2002; Solans et al., 2005).

Considering significant increment of Cmax and AUC, LaVita could be more effective the absorption rate and extent for bioavailability of vitamin A, D & E than those of general product.

**Acknowledgement**

This work was supported by the Academic Research Fund of Hoseo University, in 2010 (Project No. 2010-0092).

**References**


Pharmacokinetic Characterization of Nano-emulsion Vitamin A, D and E (LaVita) in Rats


